Maria Valente, MD

MARIA VALENTE, MD

BIOGRAPHY

Dr. Maria Valente is board-certified in medical oncology and practices at our Southpoint location. Originally from Michigan, Dr. Valente earned both her Bachelor of Science and Doctor of Medicine from the University of Michigan before setting her eyes on warmer climates and completing her residency at the University of Florida. She went on to complete her fellowship in hematology/oncology at Mayo Clinic in Jacksonville, before joining CSNF in 2007.

“It’s an exciting time to practice oncology,” she says, “because there are so many new treatments to offer patients.” Committed to treating the whole patient, Dr. Valente enjoys the collaborative approach CSNF takes through the use of social workers and registered dietitians. “I really try to work with my colleagues to ensure that all aspects of a patient’s needs are attended to; this builds a trust within our team that is unmatched at many other practices in our area.”

When not at work, Dr. Valente enjoys spending time with her three children, waterskiing and running.

Curriculum Vitae

BOARD CERTIFICATIONS

Medical Oncology

Hematology

Internal Medicine

PROFESSIONAL ASSOCIATIONS

American Society of Clinical Oncology

American Society of Hematology

American College of Physicians

FELLOWSHIP

Mayo Clinic — Jacksonville

Hematology/Oncology

RESIDENCY

University of Florida Health Science Center

EDUCATION

University of Michigan Medical School

Doctor of Medicine

University of Michigan

Bachelor of Science

RESEARCH (Principal Investigator Responsibilities)

NCT03326674

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in women with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane. Phase III, Interventional

NCT03033511

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer. Phase III, Interventional

NCT03061812

A Randomized, Open-label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for High DLL3 Expressing Small Cell Lung Cancer (SCLC) Subjects with First Relapse/Recurrence Following Front-Line Platinum-Based Chemotherapy (tahoe). Phase III, Interventional

PUBLICATIONS

Leukemia & Lymphoma

Autologous Stem Cell Transplantation and IgM Amyloidosis.

South Medical Journal

Easy Bruisability

Regional Anesthesia

Efficacy study of the rate of delivery of disposable non-mechanical pumps used for epidural infusion,